Vantis Vascular has announced the successful closing of US$10 million series B-1 preferred financing.
The company is commercialising the CrossFAST system, a dual monorail microcatheter advanced delivery system purpose-built for complex coronary and peripheral interventions.
The CrossFAST system features DuoPRO interlocking technology, a novel mechanism coupling the microcatheter to the outer delivery catheter, allowing the system to be advanced as one unit for enhanced pushability and efficient navigation.
The latest round of financing follows a raise of US$30 million to date.
“We are proud to have the ongoing support of a strong group of investors who share our vision of transforming how complex interventional procedures are performed,” said Jason Turner, chief executive officer at Vantis Vascular. “This funding is a critical milestone for Vantis and will allow us to continue our ongoing product development efforts, expand our team and initiate US commercialisation of the CrossFAST advanced delivery system for complex high-risk percutaneous coronary intervention (PCI) procedures.”
“With the completion of this financing, we plan to initiate the limited market release of the CrossFAST system in the USA,” commented Gary McCord, chief commercial officer at Vantis Vascular. “We are confident that CrossFAST can safely navigate calcified and tortuous anatomy with ease, empowering physicians to deliver life-saving therapies to patients more effectively than ever before.”
The CrossFAST integrated microcatheter advanced delivery system is commercially available in the USA as part of a limited market release. Full market release is planned in 2025.
